As Chief Commercial Officer, my responsibilities included:-the entirety of the global commercialization of services-business development leadership-marketing management-setting and implementing the strategic vision for the organization-identifying and developing strategic partnerships-alliances along with new product and service development.

-Market and technology assessment.-Capital funding strategy.-Product development.-Formulate annual budgets.-Evaluate and develop outsourcing opportunities.-Advisory Board development.-Mentor - Washington University MBA Program.

Develop, manufacture and market proprietary diagnostic and treatment technology for urology market-Directed the development of proprietary urology medical device from concept to commercialization -Recruited team of 22 associates. Reported to Chairman-Raised initial seed capital $1M and follow-up $17M capital-Recruited and hired complete R&D team - Electrical Engineers, Mechanical Engineers, Software Engineers and Techs-Formed Partnership with Washington University School of Engineering and School of Medicine-Developed Medical Advisory Board comprised of top academic schools across the United States-Obtained several US and International patents to protect intellectual property-Directed clinical trial to achieve FDA and EU approval for new biopsy and treatment systemIntroduced initial product in 2005 and directed optimized product changes in 2009. Device is currently used by Washington University, Emory, MD Anderson, New York University and several private urology practices.

MALLINCKRODT IS A $2.3 BILLION MEDICAL PRODUCTS MANUFACTURER. PURCHASED BY TYCO IN 2000.; Endovascular-Full P&L responsibility for 300 employees and $100M global business unit including remote multi-site manufacturing and warehouse facilities. Reported directly to President of Imaging Business. -Drove business unit to number one ranking among all strategic business units based on Return On Invested Capital (ROIC) and Return On Sales (ROS). -Implemented productivity improvement initiative resulting in:40% increase in volume capacity;$1.5M reduction in expenses of projected $7M;50% reduction in product rework.-Directed multi-disciplinary international team including R&D, Medical, Manufacturing and Business Development to create leading edge cardiovascular technology in a market with addressable potential in excess of $500M.-Negotiated Domestic and International distribution and supply contracts which resulted in revenues of $20 million per year to cost savings of $1.5 million. -Elected member of Mallinckrodt General Management Committee.

BOSTON SCIENTIFIC WAS A $300 MILLION INTEGRATED, HIGH GROWTH GLOBAL HEALTHCARE ENTERPRISE. PRIVATE COMPANY - IPO 1992.; $20 million Cardiac Assist DivisionResponsible for Global Sales, Marketing, R&D, Electronics Production and Field Service. Directed a 55 person organization. Annual sales $20 million. Reported to President of Cardiovascular division. Developed and implemented new 3 year strategic business plan. Revitalized flattening sales by introducing new catheter technology and convenient kit-packaging concept eagerly accepted by cardiovascular community. Added $1M to operating margins. Established focused distribution group in US and Japan resulting in an immediate 10% sales increase.

WORLD LEADER IN CENTRIFUGAL BLOOD PUMPS AND ACCESSORIES FOR THE HEALTHCARE INDUSTRY. SALES $33 MILLION. PURCHASED BY MEDTRONIC, INC. IN 1990. Director - Sales and MarketingResponsible for world wide sales and marketing, product development, new business development and strategic planning. Sales $33 million. Reported to Chairman, CEO. Established US network of twelve independent specialty distributors.Recruited and established first international distribution networkIncreased sales revenue from $500,000 to $33M over a three year period.

LARGEST AND MOST COMPREHENSIVE MANUFACTURER OF HEALTH CARE PRODUCTS SERVING THE CONSUMER, PHARMACEUTICAL AND PROFESSIONAL MARKETS. AWARDS: FIELD SALES REPRESENTATIVE OF THE YEAR; REGIONAL MANAGER OF THE YEAR

$1 BILLION CONSUMER PRODUCTS/ PHARMACEUTICAL COMPANY. PURCHASED BY PRIVATE EQUITY GROUP IN 2001.Field SalesTop Sales Representative in district and region.